1 | 10-mg dose of E5501 2G tablet | - | - | - | - | [1] 63 63 |
2 | 10-mg dose of E5501 cyclodextrin oral solution | - | - | - | - | [1] 63 63 |
3 | 10-mg dose of E5501 lipid-based oral | - | - | - | - | [1] 63 63 |
4 | 10-mg dose of E5501-P21% powder | - | - | - | - | [1] 63 63 |
5 | Acetominofene | - | - | - | - | [2] 11 11, 63 |
6 | Acetominophen | - | - | - | - | [1] 63 63 |
7 | AKR-501, YM-477 | - | - | - | - | [1] 63 63 |
8 | ALEMTUZUMAB | [1] Alemtuzumab Alemtuzumab | [1] D02802
D02802
| [1] CD52 CD52 💬 | - | [17] 13 13, 15, 19, 20, 36, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284 |
9 | Alemtuzumab, Rituximab | [2] Alemtuzumab Alemtuzumab, Rituximab | [2] D02802
D02802
,
D02994
| [2] CD52 CD52, MS4A1 💬 | - | [1] 63 63 |
10 | All-Trans Retinoid Acid(ATRA) | [1] Tretinoin Tretinoin | [1] D00094
D00094
| [3] PML PML, RARA, RARB 💬 | [12] Acute myeloid leukemia Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬 | [1] 63 63 |
11 | AMG 531 | - | - | - | - | [1] 63 63 |
12 | AMG531 | - | - | - | - | [2] 60 60, 63 |
13 | Aminophylline | [1] Aminophylline Aminophylline | [2] D00227
D00227
,
D05429
| [18] ADORA1 ADORA1, ADORA2B, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE8B 💬 | [23] Alcoholism Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 63 63 |
14 | Amoxicillin | [1] Amoxicillin Amoxicillin | [3] D00229
D00229
,
D02925
,
D07452
| - | - | [7] 6 6, 46, 63, 96, 97, 222, 299 |
15 | Amoxicillin hydrate | [1] Amoxicillin Amoxicillin | [3] D00229
D00229
,
D02925
,
D07452
| - | - | [1] 63 63 |
16 | Amoxycillin | [1] Amoxicillin Amoxicillin | [3] D00229
D00229
,
D02925
,
D07452
| - | - | [1] 63 63 |
17 | Anti-CD40L | [1] Toralizumab Toralizumab | [1] D06193
D06193
| [1] CD40LG CD40LG 💬 | [14] Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Lipid and atherosclerosis, Malaria, NF-kappa B signaling pathway, Primary immunodeficiency, Systemic lupus erythematosus, T cell receptor signaling pathway, Toxoplasmosis, Viral myocarditis 💬 | [1] 63 63 |
18 | Anti-CD40LdAb | - | - | - | - | [1] 63 63 |
19 | Anti-D | - | - | - | - | [1] 63 63 |
20 | ARGX-113 | - | - | - | - | [4] 11 11, 14, 35, 63 |
21 | Atorvastatin | [1] Atorvastatin Atorvastatin | [3] D00258
D00258
,
D00887
,
D07474
| [1] HMGCR HMGCR 💬 | [4] AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | [18] 13 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299 |
22 | Atorvastatin 10mg | [1] Atorvastatin Atorvastatin | [3] D00258
D00258
,
D00887
,
D07474
| [1] HMGCR HMGCR 💬 | [4] AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | [1] 63 63 |
23 | Atorvastatin 20mg | [1] Atorvastatin Atorvastatin | [3] D00258
D00258
,
D00887
,
D07474
| [1] HMGCR HMGCR 💬 | [4] AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | [1] 63 63 |
24 | ATRA | [1] Tretinoin Tretinoin | [1] D00094
D00094
| [3] PML PML, RARA, RARB 💬 | [12] Acute myeloid leukemia Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬 | [2] 63 63, 94 |
25 | Avatrombopag | [1] Avatrombopag Avatrombopag | [1] D10306
D10306
| [1] MPL MPL 💬 | [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [2] 60 60, 63 |
26 | Avatrombopag (proposed) | [1] Avatrombopag Avatrombopag | [1] D10306
D10306
| [1] MPL MPL 💬 | [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 63 63 |
27 | AVATROMBOPAG MALEATE | [1] Avatrombopag Avatrombopag | [1] D10306
D10306
| [1] MPL MPL 💬 | [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 63 63 |
28 | Avatrombopag tablets | [1] Avatrombopag Avatrombopag | [1] D10306
D10306
| [1] MPL MPL 💬 | [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 63 63 |
29 | Azathioprine | [1] Azathioprine Azathioprine | [2] D00238
D00238
,
D03033
| - | - | [21] 6 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162 |
30 | Blinded (Avatrombopoag tablets) | - | - | - | - | [1] 63 63 |
31 | Blisibimod | [1] Blisibimod Blisibimod | [1] D10311
D10311
| - | - | [5] 43 43, 44, 49, 63, 66 |
32 | BMS-986004 | - | - | - | - | [1] 63 63 |
33 | BMS-986004 1500 mg IV | - | - | - | - | [1] 63 63 |
34 | BMS-986004 225 mg IV | - | - | - | - | [1] 63 63 |
35 | BMS-986004 675 mg IV | - | - | - | - | [1] 63 63 |
36 | BMS-986004 75 mg IV | - | - | - | - | [1] 63 63 |
37 | BORTEZOMIB | [1] Bortezomib Bortezomib | [1] D03150
D03150
| [1] PSMB5 PSMB5 💬 | [8] Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | [16] 11 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 |
38 | BT595 | - | - | - | - | [2] 63 63, 65 |
39 | Caffeic acid tablets | - | - | - | - | [1] 63 63 |
40 | Clarithromycin | [1] Clarithromycin Clarithromycin | [1] D00276
D00276
| - | - | [8] 6 6, 63, 84, 96, 97, 222, 228, 299 |
41 | Conventional | - | - | - | - | [1] 63 63 |
42 | Corticosteroids (Aprednislon) | - | - | - | - | [1] 63 63 |
43 | CsA | - | - | - | - | [8] 19 19, 49, 50, 53, 60, 63, 222, 228 |
44 | Cyclosporin | [1] Cyclosporine Cyclosporine | [1] D00184
D00184
| [5] PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | [33] Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | [17] 38 38, 46, 49, 50, 53, 56, 60, 62, 63, 93, 95, 97, 113, 164, 222, 274, 326 |
45 | Cyclosporin A | [1] Cyclosporine Cyclosporine | [1] D00184
D00184
| [5] PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | [33] Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | [11] 46 46, 49, 53, 56, 60, 62, 63, 93, 95, 113, 164 |
46 | Cyclosporine | [1] Cyclosporine Cyclosporine | [1] D00184
D00184
| [5] PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | [33] Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | [37] 11 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
47 | Danazol | [1] Danazol Danazol | [1] D00289
D00289
| [3] AR AR, ESR1, PGR 💬 | [12] Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | [5] 60 60, 63, 64, 65, 285 |
48 | Daratumumab | [1] Daratumumab Daratumumab | [1] D10777
D10777
| [1] CD38 CD38 💬 | [7] Calcium signaling pathway Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬 | [5] 16 16, 28, 49, 63, 222 |
49 | Decitabine | [1] Decitabine Decitabine | [1] D03665
D03665
| [3] DNMT1 DNMT1, DNMT3A, DNMT3B 💬 | [3] Cysteine and methionine metabolism Cysteine and methionine metabolism, Metabolic pathways, MicroRNAs in cancer 💬 | [2] 60 60, 63 |
50 | Dexamethasone | [1] Dexamethasone Dexamethasone | [9] D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [25] 13 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
51 | Dexamethasone (1 cycle) | [1] Dexamethasone Dexamethasone | [9] D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 63 63 |
52 | Dexamethasone (4 cycles) | [1] Dexamethasone Dexamethasone | [9] D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 63 63 |
53 | Dexamethasone Abcur | [1] Dexamethasone Dexamethasone | [9] D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 63 63 |
54 | Dexamethasone and Rituximab | [2] Dexamethasone Dexamethasone, Rituximab | [10] D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
,
D02994
| [2] MS4A1 MS4A1, NR3C1 💬 | [2] Hematopoietic cell lineage Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬 | [1] 63 63 |
55 | DIACEREIN | [1] Diacerein Diacerein | [1] D07270
D07270
| - | - | [3] 36 36, 46, 63 |
56 | Diammonium glycyrrhizinate enteric-coated capsule | - | - | - | - | [1] 63 63 |
57 | Difenidramina | - | - | - | - | [2] 11 11, 63 |
58 | DIFENIDRAMINA CLORIDRATO | - | - | - | - | [2] 11 11, 63 |
59 | Doptelet | [1] Avatrombopag Avatrombopag | [1] D10306
D10306
| [1] MPL MPL 💬 | [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 63 63 |
60 | Doptelet 20 mg film-coated tablets | [1] Avatrombopag Avatrombopag | [1] D10306
D10306
| [1] MPL MPL 💬 | [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 63 63 |
61 | Doxil | - | - | - | - | [1] 63 63 |
62 | Dyphenhydramine hydrochloride | - | - | - | - | [1] 63 63 |
63 | E5501 | - | - | - | - | [1] 63 63 |
64 | E5501 40 mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | [1] 63 63 |
65 | E5501 40 mg 2 x 20-mg tablets, orally, with food | - | - | - | - | [1] 63 63 |
66 | E5501 40mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | [1] 63 63 |
67 | Efgartigimod | - | - | - | - | [3] 11 11, 35, 63 |
68 | EFGARTIGIMOD ALFA | [1] Efgartigimod alfa Efgartigimod alfa | [1] D11876
D11876
| [1] FCGRT FCGRT 💬 | - | [4] 11 11, 14, 35, 63 |
69 | Efgartigimod alpha | - | - | - | - | [1] 63 63 |
70 | Efgartigimod PH20 SC | - | - | - | - | [4] 11 11, 14, 35, 63 |
71 | ELTROMBOPAG | [1] Eltrombopag Eltrombopag | - | - | - | [5] 60 60, 63, 65, 284, 285 |
72 | Eltrombopag (Revolade) | [1] Eltrombopag Eltrombopag | - | - | - | [1] 63 63 |
73 | Eltrombopag (Revolade®) | [1] Eltrombopag Eltrombopag | - | - | - | [1] 63 63 |
74 | Eltrombopag combining rituximab | [2] Eltrombopag Eltrombopag, Rituximab | [1] D02994
D02994
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 63 63 |
75 | ELTROMBOPAG OLAMINE | [1] Eltrombopag Eltrombopag | - | - | - | [2] 60 60, 63 |
76 | Eltrombopag olamine (SB-497115-GR) | [1] Eltrombopag Eltrombopag | - | - | - | [1] 63 63 |
77 | Eltrombopag olamine, Revolade, Promacta | [1] Eltrombopag Eltrombopag | - | - | - | [1] 63 63 |
78 | Eltrombopag oral tablets | [1] Eltrombopag Eltrombopag | - | - | - | [1] 63 63 |
79 | Eltrombopag plus diacerein | [2] Diacerein Diacerein, Eltrombopag | [1] D07270
D07270
| - | - | [1] 63 63 |
80 | FCM | - | - | - | - | [2] 63 63, 222 |
81 | Gammaplex | - | - | - | - | [2] 63 63, 65 |
82 | Gammaplex, intravenous immunoglobulin | - | - | - | - | [1] 63 63 |
83 | Glycyrrhetinic Acid | - | - | - | - | [1] 63 63 |
84 | GMA161 | - | - | - | - | [1] 63 63 |
85 | GNR-069 | - | - | - | - | [1] 63 63 |
86 | HBM9161 Dose A | - | - | - | - | [1] 63 63 |
87 | HBM9161 Dose B | - | - | - | - | [1] 63 63 |
88 | Hetrombopag | [1] Hetrombopag Hetrombopag | - | - | - | [2] 60 60, 63 |
89 | Hetrombopag Olamine | [1] Hetrombopag Hetrombopag | - | - | - | [2] 60 60, 63 |
90 | High dose Dexamethasone pulses | [1] Dexamethasone Dexamethasone | [9] D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 63 63 |
91 | HMPL-523 | - | - | - | - | [2] 46 46, 63 |
92 | Huaiqihuang Granule | - | - | - | - | [1] 63 63 |
93 | Human Immunoglobulin | - | - | - | - | [2] 63 63, 65 |
94 | HUMAN IMMUNOGLOBULIN G | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [4] 14 14, 50, 63, 65 |
95 | Human normal immunoglobulin | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [9] 11 11, 13, 14, 43, 45, 50, 51, 63, 65 |
96 | HUMAN NORMAL IMMUNOGLOBULIN (IV) | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [4] 11 11, 14, 63, 65 |
97 | HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [2] 63 63, 65 |
98 | HUMAN NORMAL IMMUNOGLOBULIN FOR INTRVENOUS USE | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [1] 63 63 |
99 | Human normal immunoglobulin G (IgG > 98% purity) | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [3] 14 14, 63, 65 |
100 | HUMAX-CD38 | - | - | - | - | [2] 28 28, 63 |
101 | Hydroxychloroquine | [1] Hydroxychloroquine Hydroxychloroquine | [1] D08050
D08050
| - | - | [27] 13 13, 34, 41, 43, 44, 45, 46, 48, 49, 53, 56, 63, 66, 84, 89, 90, 96, 97, 107, 218, 222, 224, 234, 254, 271, 298, 299 |
102 | I10E | - | - | - | - | [3] 14 14, 63, 65 |
103 | Ig VENA | - | - | - | - | [2] 50 50, 63 |
104 | Ig VENA 100 ml vial | - | - | - | - | [1] 63 63 |
105 | Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set | - | - | - | - | [2] 63 63, 65 |
106 | IgG Next Generation | - | - | - | - | [2] 63 63, 65 |
107 | IGIV3I Grifols 10% | - | - | - | - | [1] 63 63 |
108 | IgNextGen 10% | - | - | - | - | [1] 63 63 |
109 | Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution | - | - | - | - | [1] 63 63 |
110 | Immunglobulin | - | - | - | - | [1] 63 63 |
111 | Immunoglobulin | - | - | - | - | [3] 13 13, 14, 63 |
112 | IMMUNOGLOBULIN G | - | - | - | - | [8] 2 2, 11, 13, 14, 49, 50, 63, 65 |
113 | Inactivated Trivalent Influenza vaccine | - | - | - | - | [1] 63 63 |
114 | INTERLEUKIN 2 | - | - | - | - | [9] 46 46, 49, 51, 56, 63, 95, 96, 97, 271 |
115 | IVIG-L | - | - | - | - | [1] 63 63 |
116 | Lansoprazole | [1] Lansoprazole Lansoprazole | [1] D00355
D00355
| [2] ATP4A ATP4A, ATP4B 💬 | [4] Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | [7] 63 63, 71, 85, 98, 166, 222, 299 |
117 | Lansoprazole, clarithromycin, amoxycillin | [3] Amoxicillin Amoxicillin, Clarithromycin, Lansoprazole | [5] D00229
D00229
,
D00276
,
D00355
,
D02925
,
D07452
| [2] ATP4A ATP4A, ATP4B 💬 | [4] Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | [1] 63 63 |
118 | LIV-GAMMA SN Inj. | - | - | - | - | [1] 63 63 |
119 | MabThera | [1] Rituximab Rituximab | [1] D02994
D02994
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [22] 11 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 |
120 | Medical Standard of Care for ITP | - | - | - | - | [1] 63 63 |
121 | Methylprednisolone | [1] Methylprednisolone Methylprednisolone | [6] D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [48] 2 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
122 | METILPREDNISOLONE | - | - | - | - | [6] 11 11, 13, 53, 56, 63, 300 |
123 | METRONIDAZOLE | [1] Metronidazole Metronidazole | [3] D00409
D00409
,
D05016
,
D05017
| - | - | [8] 46 46, 51, 63, 94, 95, 96, 97, 291 |
124 | Montelukast | [1] Montelukast Montelukast | [2] D00529
D00529
,
D08229
| [1] CYSLTR1 CYSLTR1 💬 | [2] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | [8] 6 6, 13, 46, 61, 63, 85, 98, 228 |
125 | Nanogam | - | - | - | - | [1] 63 63 |
126 | NewGam | - | - | - | - | [3] 14 14, 63, 65 |
127 | NPLATE | [1] Romiplostim Romiplostim | [1] D08990
D08990
| [1] MPL MPL 💬 | [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 63 63 |
128 | NPLATE 500 microgramos polvo para solución inyectable | [1] Romiplostim Romiplostim | [1] D08990
D08990
| [1] MPL MPL 💬 | [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 63 63 |
129 | Null | - | - | - | - | [16] 6 6, 13, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
130 | Octagam 10% | - | - | - | - | [3] 50 50, 63, 65 |
131 | Octagam® 10% | - | - | - | - | [1] 63 63 |
132 | Open Label (Avatrombopag tablets) | [1] Avatrombopag Avatrombopag | [1] D10306
D10306
| [1] MPL MPL 💬 | [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 63 63 |
133 | Orelabrutinib | [1] Orelabrutinib Orelabrutinib | [1] D12160
D12160
| [1] BTK BTK 💬 | [7] B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | [3] 13 13, 61, 63 |
134 | Orelabrutinib( higher dose) | [1] Orelabrutinib Orelabrutinib | [1] D12160
D12160
| [1] BTK BTK 💬 | [7] B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | [1] 63 63 |
135 | Orelabrutinib( lower dose) | [1] Orelabrutinib Orelabrutinib | [1] D12160
D12160
| [1] BTK BTK 💬 | [7] B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | [1] 63 63 |
136 | Other: healthy controls | - | - | - | - | [1] 63 63 |
137 | Other: RP% Measurement by FCM as a Diagnostic Test for ITP | - | - | - | - | [1] 63 63 |
138 | Palmitate | [1] Palmitic Acid Palmitic Acid | [1] D05341
D05341
| - | - | [1] 63 63 |
139 | PARACETAMOLO | - | - | - | - | [8] 2 2, 11, 14, 28, 53, 61, 63, 300 |
140 | PF-06755347 intravenous healthy participant | - | - | - | - | [1] 63 63 |
141 | PF-06755347 subcutaneous healthy participant | - | - | - | - | [1] 63 63 |
142 | PF-06755347 subcutaneous ITP | - | - | - | - | [1] 63 63 |
143 | PF-06835375 | - | - | - | - | [3] 46 46, 49, 63 |
144 | PG2 | - | - | - | - | [1] 63 63 |
145 | Placebo | - | - | - | - | [27] 3 3, 5, 6, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276 |
146 | PREDNISOLONE | [1] Prednisolone Prednisolone | [8] D00472
D00472
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [43] 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
147 | Prednisone | [1] Prednisone Prednisone | [1] D00473
D00473
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [48] 2 2, 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
148 | Privigen® | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [3] 14 14, 63, 65 |
149 | Promacta | [1] Eltrombopag Eltrombopag | - | - | - | [2] 63 63, 65 |
150 | Proteína recombinante estimulante de la megacariopoyesis | - | - | - | - | [1] 63 63 |
151 | PRTX-100 (Staphylococcal protein A) | [1] Bevifimod Bevifimod | - | - | - | [1] 63 63 |
152 | R788 | - | - | - | - | [2] 46 46, 63 |
153 | Recombinant Human Thrombopoietin | [2] Recombinant Human Thrombopoietin Recombinant Human Thrombopoietin, Thrombopoietin | - | - | - | [1] 63 63 |
154 | Recombinant human thrombopoietin (rh-TPO) | [2] Recombinant Human Thrombopoietin Recombinant Human Thrombopoietin, Thrombopoietin | - | - | - | [1] 63 63 |
155 | Recombinant Human Thrombopoietin (rhTPO) | [2] Recombinant Human Thrombopoietin Recombinant Human Thrombopoietin, Thrombopoietin | - | - | - | [1] 63 63 |
156 | Relovade | - | - | - | - | [1] 63 63 |
157 | REVOLADE | [1] Eltrombopag Eltrombopag | - | - | - | [2] 60 60, 63 |
158 | Revolade 25 mg film-coated tablets | [1] Eltrombopag Eltrombopag | - | - | - | [1] 63 63 |
159 | Revolade 50 mg film-coated tablets | [1] Eltrombopag Eltrombopag | - | - | - | [1] 63 63 |
160 | REVOLADE, PROMACTA | [1] Eltrombopag Eltrombopag | - | - | - | [1] 63 63 |
161 | RhTPO | [1] Recombinant Human Thrombopoietin Recombinant Human Thrombopoietin | - | - | - | [2] 60 60, 63 |
162 | RhTPO in combination with Rituximab | [2] Recombinant Human Thrombopoietin Recombinant Human Thrombopoietin, Rituximab | [1] D02994
D02994
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 63 63 |
163 | Rituximab | [1] Rituximab Rituximab | [1] D02994
D02994
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [49] 6 6, 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
164 | Rituximab [MabThera/Rituxan] | [1] Rituximab Rituximab | [1] D02994
D02994
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [2] 46 46, 63 |
165 | Romiplostim | [1] Romiplostim Romiplostim | [1] D08990
D08990
| [1] MPL MPL 💬 | [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [4] 60 60, 63, 64, 65 |
166 | Romiplostin | - | - | - | - | [1] 63 63 |
167 | ROZANOLIXIZUMAB | [1] Rozanolixizumab Rozanolixizumab | [1] D12182
D12182
| [1] FCGRT FCGRT 💬 | - | [3] 11 11, 14, 63 |
168 | SB-497115 | - | - | - | - | [1] 63 63 |
169 | SB-497115-GR | - | - | - | - | [1] 63 63 |
170 | SB-497115-GR 12.5mg | - | - | - | - | [1] 63 63 |
171 | SB-497115-GR 25mg | - | - | - | - | [1] 63 63 |
172 | SB-497115-GR 50 mg | - | - | - | - | [1] 63 63 |
173 | SB497115 | - | - | - | - | [2] 60 60, 63 |
174 | Sirolimus | [1] Sirolimus Sirolimus | [1] D00753
D00753
| [1] MTOR MTOR 💬 | [51] AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | [36] 6 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
175 | SM101 | - | - | - | - | [3] 49 49, 63, 66 |
176 | SM101 20mg/mL | - | - | - | - | [1] 63 63 |
177 | SM101 5mg/mL | - | - | - | - | [1] 63 63 |
178 | Standard of Care | - | - | - | - | [10] 6 6, 13, 46, 49, 51, 63, 64, 79, 171, 271 |
179 | Standard therapy (without eltrombopag): HD-DXM | [1] Eltrombopag Eltrombopag | - | - | - | [1] 63 63 |
180 | STAPHYLOCOCCAL PROTEIN A | [1] Bevifimod Bevifimod | - | - | - | [1] 63 63 |
181 | Steroids | - | - | - | - | [7] 46 46, 50, 51, 63, 66, 96, 97 |
182 | TAK-079 | - | - | - | - | [3] 11 11, 49, 63 |
183 | Takecab tablets + amoxicillin + clarithromycin (first-line eradication) Takecab tablets + amoxicillin + metronidazole (second-line eradication) | [3] Amoxicillin Amoxicillin, Clarithromycin, Metronidazole | [7] D00229
D00229
,
D00276
,
D00409
,
D02925
,
D05016
,
D05017
,
D07452
| - | - | [1] 63 63 |
184 | Thrombopoietin | [1] Thrombopoietin Thrombopoietin | - | - | - | [3] 47 47, 60, 63 |
185 | TPO | - | - | - | - | [1] 63 63 |
186 | Triple therapy | - | - | - | - | [1] 63 63 |
187 | TYSABRI | [1] Natalizumab Natalizumab | [1] D06886
D06886
| [1] ITGA4 ITGA4 💬 | [14] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | [3] 13 13, 25, 63 |
188 | UCB7665 | - | - | - | - | [3] 11 11, 14, 63 |
189 | Vonoprazan | [1] Vonoprazan Vonoprazan | [1] D11784
D11784
| [2] ATP4A ATP4A, ATP4B 💬 | [4] Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | [2] 63 63, 98 |
190 | Water | [1] Water Water | [1] D00001
D00001
| - | - | [23] 2 2, 5, 6, 13, 17, 19, 22, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 |